IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS THEREFOR IN WHICH α CHAIN REGION OF T-CELL ANTIGEN RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM Vα-Jα, AND BANKING OF NKT CELLS DERIVED FROM THE CELLS
PROBLEM TO BE SOLVED: To provide cells in which an α chain region of a T cell antigen receptor (TCR) gene derived from human NKT cells has been rearranged to a uniform Vα-Jα in a form specific to NKT-cell receptors, by a completely novel way of thinking that employs characteristics of immune cell therapy, and to provide a NKT cell banking derived from the cells, as well as to provide implantation therapies using the same.SOLUTION: The present invention relates to an immune cell therapeutic agent containing NKT cells obtained by differentiating cells in vitro in which the α chain region of a T cell antigen receptor gene has been rearranged to a uniform Vα-Jα in a form specific to NKT-cell receptors, the administration subject of the agent being an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of NKT cells. Furthermore, the present invention provides a bank of human cells in which the α chain region of a T cell antigen receptor gene has been rearranged to a uniform Vα-Jα, or NKT cells derived from the cells. The agent and cell bank are useful for preventing and/or treating cancer, infectious diseases, allergic diseases, and autoimmune disorders.SELECTED DRAWING: None【課題】免疫細胞療法の特徴を生かした、全く新規な発想の下でのヒトNKT細胞に由来するT細胞抗原受容体（TCR）遺伝子のα鎖領域がNKT細胞受容体特異的な態様で均一なVα-Jαに再構成されている細胞および該細胞由来NKT細胞のバンキング、及びそれを利用した移植治療法を提供すること【解決手段】本発明は、T細胞抗原受容体遺伝子のα鎖領域がNKT細胞受容体特異的な態様で均一なVα-Jαに再構成されている細胞をin vitroで分化させることにより得られたNKT細胞を含有してなる、免疫細胞療法剤であって、該NKT細胞と、MHC遺伝子座のうち少なくとも1座のジェノタイプが一致しない同種異系個体を投与対象とする剤を提供する。また、本発明は、T細胞抗原受容体（TCR）遺伝子のα鎖領域が均一なVα-Jαに再構成されているヒト細胞または該細胞由来NKT細胞のバンクを提供する。本発明の剤や細胞バンクは、がん、感染症、アレルギー疾患または自己免疫疾患の予防および／または治療に有用である。【選択図】なし
